SOD1 and amyotrophic lateral sclerosis: Current clinical treatments for ALS, including riluzole, along with experimental treatments such as tofersen (an antisense oligonucleotide targeting SOD1 mRNA), edaravone (an antioxidant), and relyvrio (a stress signal blocker) have demonstrated limited efficacy in halting or slowing disease progression.